Barclays PLC Acquires 24,010 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Barclays PLC increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 31.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,872 shares of the company's stock after acquiring an additional 24,010 shares during the quarter. Barclays PLC owned about 0.18% of Harmony Biosciences worth $3,471,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in HRMY. FMR LLC boosted its stake in shares of Harmony Biosciences by 1.9% during the 4th quarter. FMR LLC now owns 5,329,902 shares of the company's stock valued at $183,402,000 after purchasing an additional 101,182 shares in the last quarter. Vanguard Group Inc. boosted its position in Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after acquiring an additional 1,262,362 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after acquiring an additional 351,582 shares during the period. American Century Companies Inc. raised its position in shares of Harmony Biosciences by 28.7% in the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock worth $37,941,000 after acquiring an additional 246,140 shares in the last quarter. Finally, LSV Asset Management lifted its stake in shares of Harmony Biosciences by 23.8% in the 4th quarter. LSV Asset Management now owns 956,217 shares of the company's stock valued at $32,903,000 after purchasing an additional 184,026 shares during the period. Institutional investors own 86.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HRMY. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Needham & Company LLC reissued a "buy" rating and set a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Mizuho upped their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price target on the stock. Finally, UBS Group reduced their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences has a consensus rating of "Buy" and an average target price of $52.44.

Harmony Biosciences Stock Up 1.5 %

HRMY traded up $0.46 during trading on Friday, hitting $30.32. 857,912 shares of the company's stock traded hands, compared to its average volume of 574,597. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 14.37, a PEG ratio of 0.47 and a beta of 0.80. The company's 50 day simple moving average is $31.41 and its two-hundred day simple moving average is $34.08. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. During the same period last year, the company earned $0.45 EPS. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.